FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

DermTech's Non-Invasive Genomic Testing Shows Promise in Differentiating Melanoma from Atypical Moles

NextEdge Admin

09 Oct 2024

2 min 1 sec

DermTech, LLC, a leader in precision dermatology offering non-invasive skin genomics solutions, has published new data highlighting the effectiveness of non-invasive genomic testing in distinguishing melanoma in situ from morphologically atypical nevi when clinical and dermoscopic evaluations fall short. The study, published in the *Journal of Drugs in Dermatology* (JDD), demonstrated that non-invasive gene expression profiling (NI-GEP) helped differentiate lower-risk from higher-risk lesions, assisting clinicians in making better biopsy decisions, particularly in patients with multiple concerning moles (Peck et al., JDD, Volume 23, Issue 9, 717-723).

Gary L. Peck, MD, the lead author of the study and a recent inductee into the American Academy of Dermatology's "Titans of Dermatology," emphasized that assessing moles for melanoma remains a challenge, even for skilled dermoscopists, as some early melanomas show few morphological signs. He noted that non-invasive genomic testing offers an additional tool to aid in pigmented lesion management.

Maral K. Skelsey, MD, senior author and medical director at the Dermatologic Surgery Center of DC, where the study was conducted, added that genomic testing is essential in deciding which atypical moles to biopsy. Having used DermTech's melanoma rule-out test on over 5,000 patients, her practice has seen significant patient and business benefits from the technology.